GB0126902D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0126902D0
GB0126902D0 GBGB0126902.6A GB0126902A GB0126902D0 GB 0126902 D0 GB0126902 D0 GB 0126902D0 GB 0126902 A GB0126902 A GB 0126902A GB 0126902 D0 GB0126902 D0 GB 0126902D0
Authority
GB
United Kingdom
Prior art keywords
treatment
lower alkyl
disease
retinopathy
age
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0126902.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0126902.6A priority Critical patent/GB0126902D0/en
Publication of GB0126902D0 publication Critical patent/GB0126902D0/en
Priority to UA20040403226A priority patent/UA77446C2/uk
Priority to SA02230412A priority patent/SA02230412B1/ar
Priority to PE2002001080A priority patent/PE20030714A1/es
Priority to TW091132669A priority patent/TWI260222B/zh
Priority to IL16174702A priority patent/IL161747A0/xx
Priority to EP02787595A priority patent/EP1446382B1/en
Priority to US10/494,591 priority patent/US7091224B2/en
Priority to MXPA04004391A priority patent/MXPA04004391A/es
Priority to JP2003542148A priority patent/JP2005511602A/ja
Priority to RU2004117543/04A priority patent/RU2318811C2/ru
Priority to NZ532590A priority patent/NZ532590A/en
Priority to BR0213970-7A priority patent/BR0213970A/pt
Priority to KR1020047007040A priority patent/KR100602977B1/ko
Priority to AT02787595T priority patent/ATE496889T1/de
Priority to PL02368416A priority patent/PL368416A1/xx
Priority to PCT/EP2002/012444 priority patent/WO2003040102A1/en
Priority to PT02787595T priority patent/PT1446382E/pt
Priority to AU2002351909A priority patent/AU2002351909B2/en
Priority to CA2463968A priority patent/CA2463968C/en
Priority to DE60239073T priority patent/DE60239073D1/de
Priority to CNB028222091A priority patent/CN1300113C/zh
Priority to ES02787595T priority patent/ES2360283T3/es
Priority to HR20040411A priority patent/HRP20040411A2/hr
Priority to YU36004A priority patent/YU36004A/sh
Priority to ZA200402940A priority patent/ZA200402940B/en
Priority to CO04043909A priority patent/CO5580823A2/es
Priority to NO20042187A priority patent/NO327231B1/no
Priority to US11/374,720 priority patent/US7482369B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
GBGB0126902.6A 2001-11-08 2001-11-08 Organic compounds Ceased GB0126902D0 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
GBGB0126902.6A GB0126902D0 (en) 2001-11-08 2001-11-08 Organic compounds
UA20040403226A UA77446C2 (en) 2001-11-08 2002-07-11 Anthranilic acid amides and their use as inhibitors of vegf receptor tyrosine kinase, process for their preparation, pharmaceutical composition
SA02230412A SA02230412B1 (ar) 2001-11-08 2002-11-02 أميدات حمض الأنثرانيليك واستخدامها كمثبطاتanthranilic acid amides tyrosine kinase inhibitors لكيناز تيروسين المستقبل ل VEGF
PE2002001080A PE20030714A1 (es) 2001-11-08 2002-11-06 Derivados de amidas de acido antranilico como inhibidores del receptor de tirosina quinasa vegf
TW091132669A TWI260222B (en) 2001-11-08 2002-11-06 Anthranilic acid amides and pharmacological use thereof
YU36004A YU36004A (sh) 2001-11-08 2002-11-07 Amidi antranilne kiseline i njihova upotreba kao receptora za vegf kojem je pridružena tirozinkinaza
AT02787595T ATE496889T1 (de) 2001-11-08 2002-11-07 Anthranilsäureamid derivate und deren verwendung als vegf-rezeptor tyrosin kinase inhibitoren
AU2002351909A AU2002351909B2 (en) 2001-11-08 2002-11-07 Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors
US10/494,591 US7091224B2 (en) 2001-11-08 2002-11-07 Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors
MXPA04004391A MXPA04004391A (es) 2001-11-08 2002-11-07 Amidas de acido antranilico y su uso como inhibidores de tirosina-cinasa del receptor de vegf.
JP2003542148A JP2005511602A (ja) 2001-11-08 2002-11-07 アントラニル酸アミドおよびｖｅｇｆ受容体チロシンキナーゼ阻害剤としてのその使用
RU2004117543/04A RU2318811C2 (ru) 2001-11-08 2002-11-07 Амиды антраниловой кислоты, способ их получения и их применение, способ лечения заболевания новообразованием и фармацевтический препарат, обладающий ингибирующей активностью в отношении тирозинкиназного рецептора vegf
NZ532590A NZ532590A (en) 2001-11-08 2002-11-07 Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors
BR0213970-7A BR0213970A (pt) 2001-11-08 2002-11-07 Amidas de ácido antranìlico e uso farmacêutico dessas amidas
KR1020047007040A KR100602977B1 (ko) 2001-11-08 2002-11-07 안트라닐산 아미드 및 ｖｅｇｆ 수용체 티로신 키나제억제제로서 그의 용도
IL16174702A IL161747A0 (en) 2001-11-08 2002-11-07 Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors
PL02368416A PL368416A1 (en) 2001-11-08 2002-11-07 Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors
PCT/EP2002/012444 WO2003040102A1 (en) 2001-11-08 2002-11-07 Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors
PT02787595T PT1446382E (pt) 2001-11-08 2002-11-07 Amidas do ?cido antran?lico e sua utiliza??o como inibidores da tirosina quinase do receptor de vegf
EP02787595A EP1446382B1 (en) 2001-11-08 2002-11-07 Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors
CA2463968A CA2463968C (en) 2001-11-08 2002-11-07 Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors
DE60239073T DE60239073D1 (de) 2001-11-08 2002-11-07 Anthranilsäureamid derivate und deren verwendung als vegf-rezeptor tyrosin kinase inhibitoren
CNB028222091A CN1300113C (zh) 2001-11-08 2002-11-07 邻氨基苯甲酰胺和其作为vegf受体酪氨酸激酶抑制剂的用途
ES02787595T ES2360283T3 (es) 2001-11-08 2002-11-07 Amidas de ácido antralínico y su uso como inhibidores de tirosina quisina receptora de vegf.
HR20040411A HRP20040411A2 (en) 2001-11-08 2002-11-07 Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors
ZA200402940A ZA200402940B (en) 2001-11-08 2004-04-19 Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors.
CO04043909A CO5580823A2 (es) 2001-11-08 2004-05-12 Amidas de acido antranilico y su uso como inhibidores de tirosina-cinasa del receptor de vegf
NO20042187A NO327231B1 (no) 2001-11-08 2004-05-26 Antranilsyreamider, farmasoytske preparat, anvendelser samt fremgangsmate for fremstilling
US11/374,720 US7482369B2 (en) 2001-11-08 2006-03-14 Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0126902.6A GB0126902D0 (en) 2001-11-08 2001-11-08 Organic compounds

Publications (1)

Publication Number Publication Date
GB0126902D0 true GB0126902D0 (en) 2002-01-02

Family

ID=9925448

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0126902.6A Ceased GB0126902D0 (en) 2001-11-08 2001-11-08 Organic compounds

Country Status (28)

Country Link
US (2) US7091224B2 (enExample)
EP (1) EP1446382B1 (enExample)
JP (1) JP2005511602A (enExample)
KR (1) KR100602977B1 (enExample)
CN (1) CN1300113C (enExample)
AT (1) ATE496889T1 (enExample)
AU (1) AU2002351909B2 (enExample)
BR (1) BR0213970A (enExample)
CA (1) CA2463968C (enExample)
CO (1) CO5580823A2 (enExample)
DE (1) DE60239073D1 (enExample)
ES (1) ES2360283T3 (enExample)
GB (1) GB0126902D0 (enExample)
HR (1) HRP20040411A2 (enExample)
IL (1) IL161747A0 (enExample)
MX (1) MXPA04004391A (enExample)
NO (1) NO327231B1 (enExample)
NZ (1) NZ532590A (enExample)
PE (1) PE20030714A1 (enExample)
PL (1) PL368416A1 (enExample)
PT (1) PT1446382E (enExample)
RU (1) RU2318811C2 (enExample)
SA (1) SA02230412B1 (enExample)
TW (1) TWI260222B (enExample)
UA (1) UA77446C2 (enExample)
WO (1) WO2003040102A1 (enExample)
YU (1) YU36004A (enExample)
ZA (1) ZA200402940B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7307088B2 (en) * 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
GB0229022D0 (en) * 2002-12-12 2003-01-15 Novartis Ag Organic Compounds
DE10327719A1 (de) * 2003-06-13 2005-01-20 Schering Ag VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone
US7202260B2 (en) 2003-06-13 2007-04-10 Schering Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
US7129252B2 (en) * 2003-06-16 2006-10-31 Guoqing P Chen Six membered amino-amide derivatives an angiogenisis inhibitors
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
EP1568368A1 (en) * 2004-02-26 2005-08-31 Schering Aktiengesellschaft Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor
EP1657241A1 (en) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1655295A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
EP1820795A4 (en) 2004-12-07 2010-10-20 Toyama Chemical Co Ltd NEW ANTHRANILIC ACID DERIVATIVE OR SALT FROM IT
US7547782B2 (en) * 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
CN101265274B (zh) * 2007-02-16 2013-09-04 中国医学科学院药物研究所 嘧啶噻唑胺衍生物、及其制法和药物组合物与用途
AR073216A1 (es) 2008-08-27 2010-10-20 Leo Pharma As Derivados de piridina como receptor de vegfr-2 e inhibidores de proteina tirosina quinasa y uso farmaceutico de los mismos
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
GB201322538D0 (en) 2013-06-21 2014-02-05 Immusmol Sas Method for detecting small molecules in a sample
CN107954893A (zh) * 2017-11-28 2018-04-24 兰州纬寰生物科技有限公司 邻氨基苯甲酰胺衍生物及制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0850222B1 (en) * 1996-06-29 2003-05-28 Samjin Pharmaceutical Co., Ltd. Piperazine derivatives and process for the preparation thereof
UA71587C2 (uk) * 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
PE20030714A1 (es) 2003-10-13
MXPA04004391A (es) 2005-12-12
KR20050044382A (ko) 2005-05-12
HRP20040411A2 (en) 2005-04-30
JP2005511602A (ja) 2005-04-28
NO327231B1 (no) 2009-05-18
BR0213970A (pt) 2004-08-31
US7091224B2 (en) 2006-08-15
RU2318811C2 (ru) 2008-03-10
UA77446C2 (en) 2006-12-15
RU2004117543A (ru) 2006-01-10
CA2463968C (en) 2011-02-22
CO5580823A2 (es) 2005-11-30
CN1300113C (zh) 2007-02-14
US7482369B2 (en) 2009-01-27
TW200300087A (en) 2003-05-16
ZA200402940B (en) 2005-02-10
CA2463968A1 (en) 2003-05-15
SA02230412B1 (ar) 2007-07-31
ES2360283T3 (es) 2011-06-02
KR100602977B1 (ko) 2006-07-20
NZ532590A (en) 2005-12-23
YU36004A (sh) 2006-08-17
TWI260222B (en) 2006-08-21
NO20042187L (no) 2004-05-26
US20060178409A1 (en) 2006-08-10
DE60239073D1 (de) 2011-03-10
EP1446382A1 (en) 2004-08-18
PT1446382E (pt) 2011-05-03
IL161747A0 (en) 2005-11-20
WO2003040102A1 (en) 2003-05-15
US20050096356A1 (en) 2005-05-05
EP1446382B1 (en) 2011-01-26
PL368416A1 (en) 2005-03-21
CN1585750A (zh) 2005-02-23
AU2002351909B2 (en) 2007-04-26
ATE496889T1 (de) 2011-02-15

Similar Documents

Publication Publication Date Title
BR0213970A (pt) Amidas de ácido antranìlico e uso farmacêutico dessas amidas
BR0108374A (pt) Derivado de pirazina ou um sal deste, composição farmacêutica, e, derivado de fluoropirazina ou um sal deste
MX2007000028A (es) Derivados de nicotinamida y su uso como agentes terapeuticos.
MXPA01004256A (es) N-arilamidas del acido antranilico y del acido tioantranilico.
EA200900388A1 (ru) Бензоксазолы и оксазолопиридины, применимые в качестве ингибиторов киназ janus
GEP20022676B (en) 4-Phenyl-Pyridine Derivatives, Method for Their Production and Their Use for Treatment of Disorders Caused by Antagonist of NK-1 Receptors
WO2005056524A3 (en) Therapeutic agents useful for treating pain
SG151260A1 (en) 5-substituted-2-phenylamino-benzamides as mek inhibitors
NO20060113L (no) Pyrrolo(3,4-c)pyrazolderivater aktive som kinase inhibitorer
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
UA91332C2 (uk) Кристалічна малеатна сіль хіназоліну (варіанти), корисна як антиангіогенний агент
WO2005016867A3 (en) Anthranilic acid derivatives and their use as activators of the hm74a receptor
BR0209518A (pt) Novos derivados arilheteroalquilamina
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
MY136322A (en) Anthranilic acid amides and pharmaceutical use thereof
NO20052698L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gasatrintestinale lidelser.
EA200601418A1 (ru) ПРОИЗВОДНЫЕ 1Н-ТИЕНО [2,3-с] ПИРАЗОЛА, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ИСПОЛЬЗОВАНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ
GB0606805D0 (en) Organic compounds
NO971743D0 (no) Farmasöytisk sammensetning for profylakse og behandling av type I allergiske sykdommer
DK1174131T3 (da) Anvendelse af et middel til forbedring af astrocytfunktion til behandling af Parkinsons sygdom
ATE440835T1 (de) Heterozyklische harnstoff-derivate für die behandlung von schmerzen.
PT1572686E (pt) Derivados de amida do ácido antranílico e suas utilizações farmacêuticas
EP2266566A3 (en) Nicotinamide derivatives and their use as therapeutic agents
NO20053805L (no) Diarylmetylindenpiperidinderivater, framgangsmate for fremstilling derav, og anvendelse derav
DE69910706D1 (de) Medikament zur Behandlung von Glaukoma und ischämischer Retinopathie

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)